FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#5 | |||||
|
||||||
Junior Member
|
Sorry. Had some things to do outside in the hot sun yesterday and was busy paying the price while I wrote that. Anyway, on to BG-12...
Take all this with a grain of salt. I'm just a guy that was recently given the 'probable ms' diagnosis and all my info comes from basically a weekend of (obsessive) reading about the various treatments. It is a summary of what i read, I don't actually know what I'm talking about. ![]() In addition to increasing endorphins like LDN, BG-12 has some other benefits from what I've been reading. Here are some quotes from a good article I found here. Quote:
Quote:
Quote:
But the best part, to me, is the side effects. Quote:
Quote:
Now there were still about 30% that backed out of the clinical trials because of the side effects, so this isn't going to work on everyone. But the side effects are not going to cause permanent damage. And they get better with time if you can hang on and continue the treatment. However, I had also read that some of the other MS drugs were declared 'safe' after their trials, but turned out to be much less safe than advertised. The thing about BG-12 though, is that it has been in use for years for psoriasis. We know that people have been taking it - safely - for a long time. If you go do some fumaderm searches you'll see some great results for psoriasis and side effects that match the promises. Flushing, diarrhea, abdominal pain. All improving with time if you can continue the treatment. And nothing else. Unlike the other MS drugs, this one has already been 'in the field'. And you don't have to inject it! Sounds like a winner to me. Time will tell, but I'm almost sure this is where I want to start my treatment if I get the MS diagnosis. Also, wasn't LDN successfully used for psoriasis too? Interesting side note. |
|||||
![]() |
![]() |
"Thanks for this!" says: | ANNagain (07-20-2012), daisy.girl (07-18-2012), Dejibo (07-22-2012), KittyLady (07-18-2012), SallyC (07-18-2012) |
|
|